All In Biotech

Drug Trial Radar · NCT07873931

A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases

A Phase 1, Multicenter, Open-Label Study of BMS-986553, CD19 In Vivo Chimeric Antigen Receptor (CAR) T Cells, in Participants With Refractory Autoimmune Diseases

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 30, 2026

Primary completion

Oct 20, 2032

Study completion Jan 31, 2033

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).

Conditions

  • Systemic Lupus Erythematosus
  • Sjögren's Disease
  • Rheumatoid Arthritis
  • Idiopathic Inflammatory Myopathies
  • Systemic Sclerosis
  • Lupus Nephritis

Interventions

  • BMS-986553Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent adverse events (TEAEs)Time frame: Up to approximately 90 days post BMS-986553 infusion
  2. Number of participants with serious adverse events (SAEs)Time frame: Up to approximately 90 days post BMS-986553 infusion
  3. Number of participants with adverse events of special interest (AESIs)Time frame: Up to approximately 90 days post BMS-986553 infusion
  4. Number of participants with clinically significant laboratory abnormalitiesTime frame: Up to approximately 90 days post BMS-986553 infusion
  5. Number of participants with dose limiting toxicities (DLTs) that occur in DLT evaluation periodTime frame: 28 days after first infusion of BMS-986553

Locations

23 sites in 6 countries. Site status is shown where the registry gives one.

  • Local Institution - 0064

    Newport Beach, California

  • Local Institution - 0001

    Worcester, Massachusetts

  • Local Institution - 0004

    Ann Arbor, Michigan

  • Local Institution - 0013

    Saint Paul, Minnesota

  • Local Institution - 0062

    Omaha, Nebraska

  • Local Institution - 0007

    Morristown, New Jersey

  • Local Institution - 0052

    Great Neck, New York

  • Local Institution - 0008

    Philadelphia, Pennsylvania

  • Local Institution - 0015

    Salt Lake City, Utah

  • Local Institution - 0005

    Seattle, Washington

  • Local Institution - 0003

    Seattle, Washington

  • Local Institution - 0029

    Leuven, Belgium

  • Local Institution - 0039

    Montpellier, France

  • Local Institution - 0047

    Paris, France

  • Local Institution - 0028

    Berlin, Germany

  • Local Institution - 0060

    Erlangen, Germany

  • Local Institution - 0059

    Magdeburg, Germany

  • Local Institution - 0027

    Würzburg, Germany

  • Local Institution - 0063

    Leiden, Netherlands

  • Local Institution - 0055

    Amsterdam, North Holland, Netherlands

  • Local Institution - 0046

    Poznan, Poland

  • Local Institution - 0051

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Local Institution - 0050

    Krakow, Malopolwksie, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.